Vincerx Pharma, Inc. (VINC)
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Sector: Biotechnology
Industry: Biotechnology
Vincerx Pharma, Inc.
Nasdaq bars a compliance period at 1:250
- 1:20Reverse splitJan 28, 202520 shares → 1
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $1.09M | $915K | $939K | $340K | $173K | $173K |
| Gross Profit | -$1.09M | -$915K | -$939K | -$340K | -$173K | -$173K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $15.49M | $28.06M | $52.15M | $40.08M | $7.12M | $0 |
| Selling, General, and Administrative | $15.98M | $13.64M | $18.95M | $22.57M | $3.6M | $45K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $31.46M | $41.69M | $71.11M | $62.66M | $10.71M | $45K |
| Operating Income (EBIT) | -$31.46M | -$42.61M | -$68.72M | -$62.66M | -$10.71M | -$45K |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $8K | $0 |
| Interest Income | $472K | $1.25M | $664K | $0 | $54K | $54K |
| Other Income (Expense) | $1.39M | $2.45M | $5.74M | $23.35M | -$5.91M | $0 |
| Income Before Tax (EBT) | -$30.07M | -$40.16M | -$62.98M | -$39.31M | -$16.62M | -$45K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$30.07M | -$40.16M | -$65.37M | -$39.31M | -$16.62M | -$54K |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -5.75 | -6.84 | -10.86 | -8.30 | -11.67 | -0.03 |
| Diluted EPS | -5.75 | -6.84 | -10.86 | -8.30 | -11.67 | -0.03 |
| Weighted Average OS | 5.23M | 5.87M | 5.80M | 4.74M | 1.42M | 1.43M |
| EBITDA | -$31.46M | -$39.24M | -$62.05M | -$38.97M | -$15.83M | $9K |
| EBITDA Margin | - | - | - | - | - | - |
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $4.99M | $12.78M | $11.66M | $111.46M | $61.79M | $685 |
| Short-Term Investments | $0 | $0 | $40.8M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $4.99M | $12.78M | $52.46M | $111.46M | $61.79M | $685 |
| Accounts Receivable | $1.04M | $1.04M | $1.37M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $128K | $856K | $2M | $200K | $214K | $106 |
| Total Current Assets | $6.41M | $14.73M | $55.96M | $111.84M | $63.11M | $791 |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $0 | $2.33M | $3.24M | $4.18M | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1.59M | $0 | $0 | $0 | $65.69M | $1K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $1.16M | $81K | $1.65M | -$65.61M | $0 |
| Total Long-Term Assets | $1.59M | $3.48M | $3.32M | $5.83M | $82K | $1K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | -$791K |
| Total Assets | $8.01M | $18.22M | $59.29M | $117.68M | $63.19M | $1K |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $2.03M | $2.5M | $4.07M | $2.02M | $491K | $35K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $812 | $812 |
| Current Unearned Revenue | $0 | $0 | $0 | $4.71M | $0 | $0 |
| Other Current Liabilities | $8K | $191K | $2.19M | $1.73M | $27.31M | $9K |
| Total Current Liabilities | $5.28M | $5.61M | $9.16M | $13.92M | $37.81M | $44K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $50K | $50K | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $1.39M | $2.46M | $3.44M | $491K | $3K |
| Other Liabilities | $0 | $0 | $0 | $0 | -$3.3M | -$3.3M |
| Total Liabilities | $5.28M | $7M | $11.62M | $17.36M | $5.5M | $44K |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $8K | $2K | $2K | $2K | $1K | $1K |
| Retained Earnings | -$189.19M | -$159.11M | -$118.95M | -$55.97M | -$16.66M | -$45K |
| Comprehensive Income & Other | $119K | $8K | -$26K | -$21K | $0 | -$1K |
| Other Stockholders' Equity | $191.9M | $170.33M | $166.62M | $156.29M | $42.04M | $0 |
| Total Equity | $2.72M | $11.22M | $47.67M | $100.32M | $25.38M | -$44K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $8.01M | $18.22M | $59.29M | $117.68M | $30.88M | $0 |
| Supplementary Data | ||||||
| Total Debt | $0 | $2.5M | $3.44M | $4.17M | $0 | $0 |
| Net Debt | -$4.99M | -$10.28M | -$8.23M | -$107.28M | -$61.79M | -$685 |
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | ||||||
| Net Income | -$30.07M | -$40.16M | -$65.37M | -$39.31M | -$10.38M | -$54K |
| Depreciation & Amortization | $1.09M | $915K | $939K | $340K | $20K | $54K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $3.47M | $3.56M | $10.06M | $23.31M | $4.38M | $1K |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $328K | $200K | $0 | $0 | $0 |
| Inventory | $0 | $0 | -$200K | $0 | $0 | $0 |
| Accounts Payable | -$468K | -$1.57M | $1.05M | $1.53M | $456K | $35K |
| Other Working Capital | $290K | -$2.95M | -$2.07M | $4.08M | -$1.42M | $0 |
| Total Working Capital Change | -$178K | -$4.19M | -$1.02M | $5.61M | -$959K | $11K |
| Other Non-Cash Items | -$438K | -$583K | -$4.21M | -$23.36M | $4.66M | -$47K |
| Net Cash from Operating | -$26.13M | -$40.45M | -$59.6M | -$33.4M | -$2.28M | -$35K |
| Investing Activities | ||||||
| Capital Expenditures | $0 | $0 | $0 | -$5.26M | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$11.46M | -$11.82M | -$42.98M | $0 | $0 | $0 |
| Sales of Investments | $11.68M | $53.32M | $2.4M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | -$65.64M | -$65.64M |
| Net Cash from Investing | $212K | $41.5M | -$40.58M | -$5.26M | -$65.64M | -$65.64M |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | - |
| Common Stock Issuance | $17.87M | $114K | $280K | $47.43M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $118K | $114K | $280K | $41.02M | $64.07M | $66.46M |
| Net Cash from Financing | $17.99M | $114K | $280K | $88.45M | $64.07M | $66.46M |
| Forex Effect | $135K | -$40K | $71K | -$21K | $65.64M | $0 |
| Net Change in Cash | -$7.79M | $1.12M | -$99.83M | $49.77M | $61.79M | $790K |
| Supplementary Data | ||||||
| Operating Cash Flow | -$26.13M | -$40.45M | -$59.6M | -$33.4M | -$2.28M | -$35K |
| Capital Expenditure | $0 | $0 | $0 | -$5.26M | $0 | $0 |
| Free Cash Flow | -$26.13M | -$40.45M | -$59.6M | -$38.66M | -$2.28M | -$35K |
| Cash at Beginning | $12.85M | $11.73M | $111.56M | $61.79M | -$35K | -$825K |
| Cash at End | $5.07M | $12.85M | $11.73M | $111.56M | $61.79M | -$35K |